

DRUG METABOLISM AND DISPOSITION

A Publication of the American Society for Pharmacology and Experimental Therapeutics

February 2011

Vol. 39, No. 2

CONTENTS

SHORT COMMUNICATIONS

Delayed Elimination of SN-38 in Cancer Patients with Severe Renal Failure. *Ken-ichi Fujita, Yu Sunakawa, Keisuke Miwa, Yuko Akiyama, Minako Sugiyama, Kaori Kawara, Hiroo Ishida, Keishi Yamashita, Keiko Mizuno, Shigehira Saji, Wataru Ichikawa, Wataru Yamamoto, Fumio Nagashima, Toshimichi Miya, Masaru Narabayashi, Yuichi Ando, Takashi Hirose, and Yasutsuna Sasaki* **161**

Altered Cytochrome P450 Expression in Mice during Pregnancy. *Kwi Hye Koh, Hui Xie, Ai-Ming Yu, and Hyunyoung Jeong* **165**

Critique of the Two-Fold Measure of Prediction Success for Ratios: Application for the Assessment of Drug-Drug Interactions. *Eleanor J. Guest, Leon Aarons, J. Brian Houston, Amin Rostami-Hodjegan, and Aleksandra Galetin* **170**

ARTICLES

Morphine Brain Pharmacokinetics at Very Low Concentrations Studied with Accelerator Mass Spectrometry and Liquid Chromatography-Tandem Mass Spectrometry. *Muhammad Waqas Sadiq, Mehran Salehpour, Niklas Forsgard, Göran Posnert, and Margareta Hammarlund-Udenaes* **174**

Human CYP2S1 Metabolizes Cyclooxygenase- and Lipoxygenase-Derived Eicosanoids. *Peter Bui, Satoshi Imaizumi, Sudheer Reddy Beedanagari, Srinivasa T. Reddy, and Oliver Hankinson* **180**

CYP4F Enzymes Are Responsible for the Elimination of Fingolimod (FTY720), a Novel Treatment of Relapsing Multiple Sclerosis. *Yi Jin, Markus Zollinger, Hubert Borell, Alfred Zimmerlin, and Christopher J. Patten* **191**

Absorption and Disposition of the Sphingosine 1-Phosphate Receptor Modulator Fingolimod (FTY720) in Healthy Volunteers: A Case of Xenobiotic Biotransformation Following Endogenous Metabolic Pathways. *Markus Zollinger, Hans-Peter Gschwind, Yi Jin, Claudia Sayer, Frédéric Zécri, and Stefan Hartmann* **199**

Glutaredoxin and Thioredoxin Can Be Involved in Producing the Pharmacologically Active Metabolite of a Thienopyridine Antiplatelet Agent, Prasugrel. *Katsunobu Hagihara, Miho Kazui, Atsushi Kurihara, Kazuishi Kubota, and Toshihiko Ikeda* **208**

Disposition and Metabolism of [¹⁴C]SB-649868, an Orexin 1 and 2 Receptor Antagonist, in Humans. *Cecilia Renzulli, Mike Nash, Mark Wright, Steven Thomas, Stefano Zamuner, Mario Pellegratti, Paolo Bettica, and Gary Boyle* **215**

Metabolism and Disposition of ¹⁴C-Labeled Peliglitazar in Humans. *Lifei Wang, Carey Munsick, Sean Chen, Samuel Bonacorsi, Peter T. Cheng, W. Griffith Humphreys, and Donglu Zhang* **228**

Effects of Ketoconazole on the In Vivo Biotransformation and Hepatobiliary Transport of the Thrombin Inhibitor AZD0837 in Pigs. *Elin M. Matsson, Johan E. Palm, Ulf G. Eriksson, Pernilla Bottner, Anna Lundahl, Lars Knutson, and Hans Lennernäs* **239**

Influence of Cremophor EL and Genetic Polymorphisms on the Pharmacokinetics of Paclitaxel and Its Metabolites Using a Mechanism-Based Model. *Martin N. Fransson, Henrik Gréen, Jan-Eric Litton, and Lena E. Friberg* **247**

Tissue Distribution and Elimination of [¹⁴C]Apixaban in Rats. *Lifei Wang, Kan He, Brad Maxwell, Scott*

Continued on next page

<i>J. Grossman, Larry M. Tremaine, W. Griffith Humphreys, and Donglu Zhang</i>	256	Brain Tissue Binding of Drugs: Evaluation and Validation of Solid Supported Porcine Brain Membrane Vesicles (TRANSIL) as a Novel High-Throughput Method. <i>Raffaele Longhi, Silvia Corbioli, Stefano Fontana, Federicia Vinco, Simone Braggio, Lydia Helmdach, Jürgen Schiller, and Hinnerk Boriss</i>	312
Attenuation of Intestinal Absorption by Major Efflux Transporters: Quantitative Tools and Strategies Using a Caco-2 Model. <i>Xuena Lin, Suzanne Skolnik, Xiaohui Chen, and Jianling Wang</i>	265	Correlation between Bilirubin Glucuronidation and Estradiol-3-Glucuronidation in the Presence of Model UDP-Glucuronosyltransferase 1A1 Substrates/Inhibitors. <i>Jin Zhou, Timothy S. Tracy, and Rory P. Remmel</i>	322
The Utility of In Vitro Data in Making Accurate Predictions of Human P-Glycoprotein-Mediated Drug-Drug Interactions: A Case Study for AZD5672. <i>Robert Elsby, Michael Gillen, Caroline Butters, Gemma Imisson, Pradeep Sharma, Veronica Smith, and Dominic D. Surry</i>	275	Ethanol Induction of CYP2A5: Permissive Role for CYP2E1. <i>Yongke Lu, Jian Zhuge, Defeng Wu, and Arthur I. Cederbaum</i>	330
Tissue Distribution and Characterization of Drug-Related Material in Rats and Dogs after Repeated Oral Administration of Casopitant. <i>Sabrina Paggiarusco, Silvia Martinucci, Ellenia Bordini, Lidia Miraglia, Domenico Cufari, Luca Ferrari, and Mario Pellegatti</i>	283	☐ Identification and Validation of Novel Human Pregnane X Receptor Activators among Prescribed Drugs via Ligand-Based Virtual Screening. <i>Yongmei Pan, Linhao Li, Gregory Kim, Sean Ekins, Hongbing Wang, and Peter W. Swaan</i>	337
A Pharmacokinetic Model for Evaluating the Impact of Hepatic and Intestinal First-Pass Loss of Saquinavir in the Rat. <i>R. Lledó-García, A. Náchér, V. G. Casabó, and M. Merino-Sanjuán</i>	294	☐ Inactivation of Cytochrome P450 (P450) 3A4 but not P450 3A5 by OSI-930, a Thiophene-Containing Anticancer Drug. <i>Hsia-lien Lin, Haoming Zhang, Christine Medower, Paul F. Hollenberg, and William W. Johnson</i>	345
☐ Elucidation of a Novel Bioactivation Pathway of a 3,4-Unsubstituted Isoxazole in Human Liver Mitochondria: Formation of a Glutathione Adduct of a Cyanoacrolein Derivative after Isoxazole Ring Opening. <i>Jian Yu, James J. Folmer, Valerie Hoesch, James Doherty, James B. Campbell, and Doug Burdette</i>	302	ERRATUM	
		Correction to “Identification of Clinically Utilized Drugs that Activate Pregnane X Receptors”	351

☐ Supplemental material is available online at <http://dmd.aspetjournals.org>.

About the cover: Molecular modeling showing the binding of OSI-930 in the active sites of P450 3A4 (A) and P450 3A5 (B). See the article by Lin et al. on page 345 of this issue.